New molecular targeted therapies integrated with radiation therapy in lung cancer

Clinical Lung Cancer

Volumn 11, Issue 2, 2010, Pages 91-97

  Provencio, Mariano ^a   Sánchez, Antonio ^a   Garrido, Pilar ^b   Valcárce, Francisco ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b Hospital Ramón y Cajal   (Netherlands)

Author keywords

Bevacizumab; Cetuximab; Chemoradiotherapy; Erlotinib; Gefitinib; HSP90; Stage III non small cell lung cancer

Indexed keywords

2 [[3 [4 [5 [2 (3 FLUOROANILINO) 2 OXOETHYL] 1H PYRAZOL 3 YLAMINO] 7 QUINAZOLINYLOXY]PROPYL](ETHYL)AMINO]ETHYL DIHYDROGEN PHOSPHATE; ANGIOGENESIS INHIBITOR; AURORA KINASE INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; PEMETREXED; PHA 680632; PLACEBO; RAPAMYCIN; SU 11657; THALIDOMIDE; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR; VORINOSTAT;

ANTIANGIOGENIC ACTIVITY; CANCER RADIOTHERAPY; CELL DEATH; CELL PROLIFERATION; DNA REPAIR; DRUG EFFICACY; DRUG SAFETY; ESOPHAGITIS; HEART ARRHYTHMIA; HUMAN; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE;

EID: 77952511165     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2010.n.012     Document Type: Review

References (69)

1. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 2004; 22:330-353
2. Vokes EE, Herndon JE II, J, Kelley MJ, et al. Induction chemotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007; 25:1698-1704
3. Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 2008; 13(suppl 1):5-13.
4. Rajan A, Gutierrez M, Giaccone G. Newer opportunities in systemic therapy of lung cancer. Ann Oncol 2008; 19:vii31-7.
5. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 2004; 22:777-784 (Pubitemid 41103588)
6. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT. J Clin Oncol 2004; 22:785-794 (Pubitemid 41103589)
7. Gaztemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25:1545-1552
8. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 25:1545-1552
9. Akimoto T, Hunter NR, Buchmiller L, et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability, almost in murine carcinomas. Clin Cancer Res 1999; 5:2884-2890
10. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000; 6:2166-2174
11. Raben D, Heffrich B, Chan DC, et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 2005; 11:795-805.
12. Tanaka T, Munshi A, Brooks C, et al. Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity. Clin Cancer Res 2008; 14:1266-1273
13. Chinnaiyan P, Huang S, Vallabhaneni G, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005; 65:3328-3335
14. Govidan R, Bogart J, Wang L, et al. Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407. J Clin Oncol 2009; 27(suppl): (abstract 7505).
15. Hughes S, Liong J, Miah A, et al. A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study. J Thorac Oncol 2008; 3:648-651
16. Jensen AD, Münter MW, Bischoff H, et al. Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518). BMC Cancer 2006; 6:122.
17. Komaki R, Swann S, Curran W, et al. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA7B non-small cell lung cancer (NSCLC): An interim overall toxicity report of the RTOG 0324 trial. Int J Rad Oncol Biol Phys 2005; 63(suppl):s44 (abstract 72).
18. Blumenschein G, Paulus R, Curran W, et al. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): a report of the 2 year and median survival (MS) for the RTOG 0324 trial. J Clin Oncol 2008; 26(suppl):401s (abstract 7516).
19. Van den Heuvel MM, Belderbos J, Dalesio O, et al. Erlotinib as maintenance therapy after concurrent chemoradiotherapy in patients (p) with stage III nonsmall cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study. J Clin Oncol 2009; 27: (abstract 7537).
20. Nyman J, Hallqvist A, Brodin O, et al. Concurrent cetuximab and radiotherapyafter docetaxel-cisplatin induction chemotherapy in stage III NSCLC: a phase II study from the Swedish Lung Cancer Study Group. J Thorac Oncol 2009; 4: supplement 1, S373, 2009 (abstract C6.5)
21. Bonner JA, Harari PM, Azarnia N, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578
22. Stinchcombe TE, Morris DE, Lee CB, et al. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74GY) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. J Thorac Oncol 2008; 3:250-257
23. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008; 26:2450-2456
24. Keedy VL, Arteaga CL, Johnson DH. Does Gefitinib shorten lung cancer survival? Chaos redux. J Clin Oncol 2008; 26:2428-2430
25. Eberhard DA, Johnson BE, Ameir LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23:5900-5909
26. Bhutani M, Pathak AK, Mao L. SWOG S0023: What meets the eye may be only half the truth. J Clin Oncol 2008; 26:4848-4853
27. Stewart DJ. Gefitinib maintenance in stage III non-small-cell lung cancer. J Clin Oncol 2008; 26:4849
28. Ready N, Jaenne P, Herndon J, et al. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer: a CALGB stratified phase II trial. Proc Am Soc Clin Oncol 2006; 24:375s (abstract 7046).
29. Choong NW, Mauer AM, Haraf DJ, et al. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol 2008; 3:1003-1011
30. Casal J, Vázquez S, León L, et al. Erlotinib as maintenance therapy after concurrent chemoradiotherapy in patients (p) with stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study. J Clin Oncol 2009; 27(suppl): (abstract 7537).
31. O'Reilly MS. Radiation combined with antiangiogenic and antivascular agents. Semin Radiat Oncol 2006; 16:45-50.
32. García-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300:1155-1159
33. Vaupel P. Tumor microenviromental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004; 14:198-206.
34. Lee CG, Hejin M, di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000; 60:5565-5570
35. Abdollahi A, Lipson KE, Han X, et al. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 2003; 63:3755-3763
36. Camphausen K, Purow B, Sproull M, et al. Influence of in vivo growth on human glioma cell line gene expression: convergent profiles under orthotopic conditions. Proc Natl Acad Sci USA 2005; 102:8287-8292
37. Shibuya K, Komaki R, Shintani T, et al. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2007; 69:1534-1543
38. Spiegel D, Hainsworth J, Farley C, et al. Tracheoesophageal (TE) fistula development in a phase II trial of concurrent chemoradiation (CRT) and bevacizumab (B) in limited-stage small-cell lung cancer (LS-SCLC). J Clin Oncol 2008; 26(suppl):410s (abstract 7554).
39. Socinski MA, Morris D, Stinchcombe T, et al. Incorporation of bevacizumab and erlotinib with induction and concurrent carboplatin/ paclitaxel and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer. J Clin Oncol 2008; 26(suppl):401s (abstract 7517).
40. Socinski MA, Stinchcombe TE, Halle JS, et al. Incorporation of bevacizumab (B) and erlotinib (Er) with induction (Ind) and concurrent (Conc) carboplatin (Cb)/ paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27(suppl): (abstract 7528).
41. Schiller JH, Dahlberg SE, Mehta M, et al. A phase III trial of carboplatin, paclitaxel, and thoracic radiation therapy with or without thalidomide in patients with stage III non-small cell carcinoma of the lung (NSCLC): E3598. J Clin Oncol 2009; 27(suppl): (abstract 7503).
42. Huber PE, Bischof M, Jenne J, et al. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 2005; 65:3643-3655
43. Citin D, Menard C, Camphausen K. Combining radiotherapy and angiogenesis inhibitors: clinical trial design. Int J Radiat Oncol Phys 2006; 1:15-25.
44. Hennequin C. Les therapeutiques ciblées en association avec la radiothérapie dans le cancer bronchique. Cancer Radiother 2007; 11:77-83.
45. Toulany M, Kasten-Pisula U, Brammer I, et al. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Clin Cancer Res 2006; 12:4119-4126
46. Meric-Bernstam F, González-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009; 27:2278-2287
47. Kim IA, Bae SS, Fernades J, et al. Selective inhibition of Ras, phosphoinositidine 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res 2005; 65:7902-7910
48. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003; 3:371-377 (Pubitemid 36908940)
49. Inoki K, Corradetti MN. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005; 37:19-24.
50. Manegold PC, Paringer C, Kulka U, et al. Antiangiogenic Therapy with Mammalian Target of Rapamycin Inhibitor RAD001 (Everolimus) Increases Radiosensitivity in Solid Cancer. Clin Cancer Res 2008; 14:892-900.
51. Hildebrandt MA, Yang H, Hung CH, et al. Genetic variations in the PI3K/ PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 2009; 27:857-871
52. Neckers L, Kern A, Tsutsumi S. Hsp90 inhibitors disrupt mitochondrial homeostasis in cancer cells. Chem Biol 2007; 14:1204-1206
53. Shimamura T, Shapiro GI. Heat shock protein 90 inhibition in lung cancer. J Thorac Oncol 2008; 3(6 suppl):S152-9.
54. Minucci S, Pelici PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6:38-51.
55. Dote H, Cerna D, Burgan WE, et al. ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition. Cancer Res 2005; 65:6967-6975
56. Kim WY, Oh SH, Woo JK, et al. Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha. Cancer Res 2009; 69:1624-1632
57. Teicher BA. Newer cytotoxic agents: attacking cancer broadly. Clin Cancer Res 2008; 14:1610-1613
58. Gautschi O, Heigway J, Mack P, et al. Aurora Kinases as anticancer drug targets. Clin Cancer Res 2008; 14:1639-1648
59. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009; 8:547-566
60. Mora-Bermudez F, Gerlich D, Ellenberg J. Maximal chromosomes compaction occurs by axial shortening in anaphase and depends on aurora kinase. Nat Cell Biol 2007; 9:822-831
61. Guan Z, Wang XR, Zhu XF, et al. Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. Cancer Res 2007; 67:10426-10444
62. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10:262-267
63. Soncini C, Carpinelli P, Gianelli L, et al. PHA-680632 a novel aurora kinase inhibitor with potent antitumoral activity. Clin Cancer Res 2006; 12:4080-4089
64. Wilkinson RW, Odedra R, Heaton SP, et al. AZD 1152, a selective inhibitor of aurora B kinase, inhibits human xenograft growth by inducing apoptosis. Clin Cancer Res 2007; 13:3682-3688
65. Rubin EH, Shapiro GI, Stein MN, et al. A phase I clinical and pharmacokinetic(PK) trial of aurora kinase (AK) inhibitor MK-0457 in cancer patients. J Clin Oncol 2006; 24(suppl):123s (abstract 3009).
66. Hata T, Furukawa T, Sunamura M, et al. RNA interference targeting aurora kinase A suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res 2005; 65:2899-2905
67. Tao Y, Zhang P, Frascogna V, et al. Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells. Br J Cancer 2007; 97:1664-1672
68. Tao Y, Zhang P, Girdler F, et al. Enhancement of radiation response in p53- deficient cancer cells by Aurora-B kinase inhibitor AZD1152. Oncogene 2008; 27:3244-3255
69. Kim KW, Mutter RW, Willey CD, et al. Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests. Int J Radiat Oncol Biol Phys 2007; 67:1519-1525